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Background: Dual-eligible (Medicare/Medicaid) beneficiaries are randomly assigned to a benchmark
plan, which provides prescription drug coverage under the Part D benefit without consideration of their
prescription drug profile. To date, the potential for beneficiary assignment to a plan with poor formulary
coverage has been minimally studied and the resultant financial impact to beneficiaries unknown.
Objective: We sought to determine cost variability and drug use restrictions under each available 2010
California benchmark plan.
Methods: Dual-eligible beneficiaries were provided Part D plan assistance during the 2010 annual
election period. The Medicare Web site was used to determine benchmark plan costs and prescription
utilization restrictions for each of the six California benchmark plans available for random assignment in
2010. A standardized survey was used to record all de-identified beneficiary demographic and plan
specific data. For each low-income subsidy-recipient (n = 113), cost, rank, number of non-formulary
medications, and prescription utilization restrictions were recorded for each available 2010 California
benchmark plan. Formulary matching rates (percent of beneficiary’s medications on plan formulary) were
calculated for each benchmark plan.
Results: Auto-assigned beneficiaries had only a 34% chance of being assigned to the lowest cost plan; the
remainder faced potentially significant avoidable out-of-pocket costs. Wide variations between
benchmark plans were observed for plan cost, formulary coverage, formulary matching rates, and
prescription utilization restrictions.
Conclusions: Beneficiaries had a 66% chance of being assigned to a sub-optimal plan; thereby, they faced
significant avoidable out-of-pocket costs. Alternative methods of beneficiary assignment could decrease
beneficiary and Medicare costs while also reducing medication non-compliance.

Keywords: Medicare Part D, benchmark plans, dual-eligible, Medicaid, prescription drug costs, drug utilization

restrictions

doi: http://dx.doi.org/10.5600/mmrr.003.02.a01

Patel, R. A., Walberg, M. P., Woelfel, J. A., Amaral, M. M., Varu, P.

E1

MMRR

2013: Volume 3 (2)

Background
The prescription drug benefit, Medicare Part D, available to Medicare beneficiaries through
private insurance plans is entering its eighth year of operation. As of 2010, of the 46.5 million
beneficiaries eligible for Medicare Part D nearly 4.67 million (10%) resided in California, the
highest number of any state (CMS, 2010). Of all eligible beneficiaries, 68.9% (27.6 million) have
enrolled in a Medicare Part D plan, with most others receiving benefits through their former
employer or union group (CMS, 2010).
In 2009, the Centers for Medicare & Medicaid Services (CMS) estimated that almost 10
million (36%) beneficiaries enrolled in a Medicare Part D plan had lower costs through
enrollment in the low-income subsidy (LIS; Kaiser Family Foundation, 2009). Individuals who
qualify for the LIS have an annual income up to 150% of the Federal Poverty Level ($14,570 for a
family of two in 2010) and limited assets (<$25,010 for a married couple living together in 2010).
Of those eligible for LIS, 8.1 million automatically received the subsidy as full dual-eligible
beneficiaries (Medicare and Medicaid recipients) or through receipt of either Supplemental
Security Income or the Medicare Savings Programs (Kaiser Family Foundation, 2009). As of
February 2010, 1.22 million LIS recipients resided in California; the highest number of LIS
beneficiaries of any state (CMS, 2010).
The challenges faced by dual-eligible beneficiaries include, but are not limited to, having
a higher reported prevalence of physical and cognitive impairments (Ponce, Ku, Cunningham, &
Brown, 2006; Summer, Nemore, & Finberg, 2007; Donohue, 2006). Since the inception of
Medicare Part D in 2006, full-benefit, dual-eligible beneficiaries have been automatically
enrolled in a stand-alone prescription drug plan (PDP) in the hope of safeguarding this
vulnerable population. This automatic enrollment into a regional low-income ‘benchmark’ plan
was required by Congress and implemented by CMS (Nemore, 2005), a process that has since
been expanded to include all LIS-receiving beneficiaries (Summer, Hoadley, Hargrave,
Cubanski, & Neuman, 2008).
Each Medicare region has at least one benchmark plan to which LIS-recipients can be
automatically enrolled, provided that two criteria are met: (1) the monthly PDP premium is at
or below the regional benchmark premium and (2) the PDP offers a standard benefit (Summer
et al., 2008; Hoadley, Hargrave, Merrell, & Summer, 2008). According to federal law, the
regional benchmark premium is based on an enrollment-weighted average of the monthly
premiums between all PDPs and Medicare-Advantage prescription drug plans (MA-PDs)
offered in the region (Summer et al., 2008). Moreover, CMS annually examines each Medicare
Part D plan to determine if it is “actuarially equivalent,” or at least as good, as the standard
benefit plan. Once a plan is designated as a benchmark plan, LIS beneficiaries are automatically
and randomly assigned (“random assignment”) evenly between all available regional benchmark
plans (U.S. GAO, 2007). Auto-assigned beneficiaries are also randomly reassigned to a new
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benchmark plan if their current plan no longer remains a benchmark plan in the upcoming year
(Kaiser Family Foundation, 2009; Summer et al., 2008). Of the 47 PDPs available in California in
2010, 7 plans (15%) met the necessary criteria required for designation as a benchmark plan
(Kaiser Family Foundation, 2009).
The advantages of random assignment include the assurance that each dual-eligible
beneficiary is enrolled into a benchmark plan; thereby, eliminating the monthly plan premium
and requiring only nominal co-pays for formulary covered medications. However, a beneficiary
may be required to pay the full cost for a non-formulary medication unless a coverage
determination is successfully made to the Part D plan, or a substitution to a formulary covered
medication is made by the provider. This potential increase in out-of-pocket (OOP) costs for
non-formulary medications is probable, based on observed formulary differences of California
benchmark plans in 2008 (California HealthCare Foundation, 2008). A study by the Department
of Health and Human Services reported that only 18% of LIS-receiving beneficiaries were
assigned to benchmark plans covering the most commonly used drugs (Levinson, 2006). An
analysis by Maine officials prior to the start of Medicare Part D found that random assignment
resulted in one in five dual-eligible beneficiaries having formulary matching rates (the
percentage of a beneficiary’s medications included on the plan formulary) below 20% (U.S.
GAO, 2007). Furthermore, only one-third of the beneficiaries in this study were automatically
assigned to plans covering all of their medications, while approximately 30% were in plans that
covered fewer than 60% of their drugs (U.S. GAO, 2007). Collectively, this research suggests that
under random assignment, differences in plan formularies can lead to significant variability in
both beneficiary and governmental costs and/or annual changes in medication utilization
dictated by varying formulary coverage.
In recognition of the potential issues associated with random assignment, several state
pharmacy assistance programs utilized beneficiary-centered assignment for certain Medicare
beneficiaries during the first year of Medicare Part D plan availability (Hoadley, Summer,
Thompson, Hargrave, & Merrell, 2007). Under beneficiary-centered assignment, a beneficiary
will be reassigned to a different benchmark plan if the randomly assigned plan covers fewer than
85% of their regular prescription medications (formulary matching rates < 85%; Hoadley et al.,
2007). Maine is the only state that continues to use beneficiary-centered assignment. A study
examining the estimated cost differences between benchmark plans in five regions found that
beneficiary-centered assignment can lower beneficiary OOP costs by approximately $450 from
the median benchmark plan costs (Hoadley et al., 2008).
Although prior studies have determined the percentage of medications covered on
benchmark plan formularies, to-date no study has looked at patient-level variability in
beneficiaries’ total OOP costs, nor the employment of utilization management tools for each
available regional benchmark plan based on the exact array of prescription medications used by
LIS-recipients. The present study seeks to calculate the estimated OOP cost for LIS-recipients,
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and the number of their medications affected by restriction processes under each California
benchmark plan to which beneficiaries could be randomly assigned in 2010.

Methods
Study Design
This cross-sectional study examined the variation in beneficiary OOP costs between each of the
2010 benchmark plans offered in California. The increased cost of non-formulary medications
and frequency of plan restrictions were also examined between benchmark plans.
Data Collection
In total, 11 outreach events were held in 7 different Central/Northern California cities during
the 2010 annual election period (November 15 and December 31, 2009). Sites at which events
were conducted included senior centers, housing complexes, community clinics, and institutions
of worship. In total, 286 Medicare beneficiaries were assisted during the scheduled events, 40%
(n = 113) of whom were full dual-eligible LIS-recipients without any additional creditable
coverage (e.g., Veterans Affairs or employer health benefits).
The Medicare Plan Finder tool on the Medicare Web site (www.medicare.gov) was used
to confirm the subsidy status, and calculate the estimated annual cost (EAC) of each benchmark
plan for each LIS-recipient outreach attendee. The EAC is the total estimated OOP cost under a
Part D plan that a beneficiary could be expected to incur during a given calendar year and
includes all premium, deductible, and co-payment/co-insurance amounts at each coverage level.
The EAC also includes the expected OOP costs for all non-formulary medications until they
reach catastrophic coverage. The only OOP costs incurred by full dual-eligible beneficiaries
enrolled in a benchmark plan are the nominal co-pay amounts associated with formulary
covered medications. Beneficiaries receiving a partial LIS subsidy, or those who enroll in a nonbenchmark plan, will also incur a monthly premium that is included in the EAC. Ultimately, the
EAC of each Part D plan for each beneficiary is based on their medication profile (medication
name, strength, and refill quantity and frequency), subsidy status, and pharmacy preference,
along with the plan’s formulary and cost-sharing structure.
The EAC and rank (based on EAC) of each of the six California benchmark plans in 2010
to which beneficiaries could be randomly assigned were recorded for all 113 confirmed full dualeligible LIS-recipients. Due to extenuating circumstances, CMS did not auto-assign any
beneficiaries to a 7th California benchmark plan in 2010 (WellCare Classic offered by WellCare).
In addition, the number of prescription medications that were not on formulary, required a
prior authorization, had quantity limits, or had step therapy restrictions were recorded for the
same six plans based on each individual beneficiary’s prescription medication profile.
The formulary matching rates were calculated as the percent of the beneficiary’s
medications on each benchmark plan formulary. For example, a beneficiary taking eight
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medications with only seven on the plan formulary would have a formulary matching rate of
87.5%. The percent increase in EAC was calculated for participants with at least one nonformulary drug using the benchmark plan with the lowest EAC as the reference. This cost
increase was further subdivided to include only those who had a formulary matching rate of less
than 80%. For example, if a benchmark plan with a formulary matching rate of 75% was
estimated to cost $1000, and the lowest EAC benchmark plan was $50, the percent increase
would be 2000%. Lastly, the average EAC increase of suboptimal plan selection (a benchmark
plan with a lower EAC was available) was calculated for each beneficiary and each benchmark
plan.
Beneficiary demographic and plan cost data were collected and recorded via a
standardized survey. Both the outreach encounter and data collection were performed by
trained student pharmacists. All activities were performed under the oversight of licensed
pharmacists employed as faculty members at the University of the Pacific, Thomas J. Long
School of Pharmacy and Health Sciences. Approval to conduct this research was obtained from
the Institutional Review Board at the University of the Pacific.
Statistical Analysis
Descriptive statistics were used to summarize the demographic characteristics of study
participants. Cost data comparing the EAC of the six benchmark plans were analyzed using the
Repeat-measures ANOVA test. Tukey’s HSD post-hoc test was used to determine differences
between individual plans. All inferential statistics were performed at an alpha level of 0.05. Data
analyses were performed using SPSS, version 17.0 (Chicago, IL).

Results
The demographic characteristics of the study population are summarized in Exhibit 1. On
average, participants used approximately six prescription medications per month, with over 30%
of participants taking at least seven medications on a monthly basis. Approximately 62% of
medications taken by LIS-recipients were generic.
The average EAC between benchmark plans varied from a low of $302 to a high of $1223
(Exhibit 2). First Health Part D Premier and Health Net Orange Option 1 had significantly lower
estimated annual costs than the other four benchmark plans (P < 0.01; Exhibit 2). The frequency
of being the lowest EAC PDP ranged from 18.6% to 46.9%, a 2.5-fold difference across
benchmark plans. Three of the six benchmark plans had at least one instance in which they were
the highest cost PDP in the entire region. The largest range observed between the lowest and
highest EAC benchmark plans was over $12,000 for one beneficiary.
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Exhibit 1. Dual-eligible (Medicare/Medicaid) beneficiary
demographics (n = 113)
Characteristics
Count
%
Age, y
Mean + SD
73.2 + 9.1
< 65
11
(10)
65-74
51
(46)
75-84
39
(36)
> 85
9
(8)
Health Status, No. (%)
Excellent
2
(2)
Good
32
(28)
Fair
38
(34)
Poor
21
(19)
Refused to answer
1
(1)
Prescription Medications
Per Month
Mean + SD
5.8 + 3.3
1–2
13
(12)
3–6
64
(57)
7–10
26
(23)
11+
10
(9)
Generic, %
62.3
SOURCE: Information collected via beneficiary survey during the
personalized intervention.

On average, only two of the six benchmark plans were the lowest EAC PDP in 2010 for each
beneficiary, indicating that study participants had a two in three chance of being randomly
assigned to a sub-optimal benchmark plan. When ranked as the lowest EAC benchmark plan in
the region, the mean EAC varied between $60 and $94. A non-benchmark PDP was associated
with the lowest EAC in 2010 for 5 (4.4%) of the study’s 113 participants.
Formulary coverage varied significantly between the six benchmark plans with 16
(14.2%) participants taking at least one medication not covered on the Health Net plan
formulary compared to 65 (57.5%) beneficiaries taking one or more medications absent on the
Blue Cross formulary. Compared to the lowest cost benchmark plan, EAC increased by over
1500% if one or more of the participant’s medications was not covered by the plan formulary.
The EAC increase due to non-formulary medications ranged from a low of 1,059% (Health Net)
to a high of 1,855% with Fox Value (Exhibit 2). Enrollment in a suboptimal plan was associated
with a $339 to $1,884 increase in EAC (Exhibit 2).
Differences in formulary matching rates were also found. Only 3.5% of study participants
had a formulary matching rate less than 80% with Health Net, as compared to 31% with either
Blue Cross or BravoRx (Exhibit 2). Approximately 18% of study participants had a formulary
matching rate less than 80% across all benchmark plans. The mean cost increase for benchmark
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plans with a formulary matching rate less than 80% was 2034% and ranged from a low of 1614%
to a high of 2426%.
Exhibit 2. Benchmark plan estimated annual costs (EAC), non-formulary medications (NF Rx), formulary matching
rates, and potential cost ramifications for study beneficiaries (n = 113)
Benchmark Plan Name1
Metric
AS
BC
BR
FH
FV
HN
EAC in $, Mean + SD

860 + 1600

1223 + 1552

1174 + 1772

302 + 5902

1157 + 1847

369 + 9782

Lowest EAC
Frequency, No. (%)

37 (32.7)

21 (18.6)

31 (27.4)

53 (46.9)

53 (46.9)

51 (45.1)

Lowest EAC, Mean $

80

60

74

90

64

94

Suboptimal plan EAC
increase in $, Mean
+ SD
Beneficiaries w/ > 1
NF Rx, No. (%)
No. NF Rx per
beneficiary, Mean
Mean EAC inc. w/ > 1
NF Rx, %
Formulary matching
rates < 80%, No. (%)

1100 + 1637

1359 + 1440

1442 + 1736

339 + 731

1884 + 1958

432 + 1035

47 (41.6)

65 (57.5)

56 (49.6)

17 (15)

56 (49.6)

16 (14.2)

1.18

1.38

1.25

Mean EAC inc. w/
formulary matching
rates < 80%, %

1960

1.43
1556
19 (16.8)

1.55
1837
35 (31)
2426

1.71
1830
35 (31)
2255

1167
6 (5.3)
2122

1855

1059

22 (19.5)
1828

4 (3.5)
1614

AS, Advantage Star Plan by RxAmerica; BC, BlueCross; BR, Bravo Rx; FH, First Health Part D Premier; FV, Fox Value Plan; HN, Health Net
Orange Option 1
2
P < 0.01 (Tukey's HSD test) for comparison of FH or HN to other plans
SOURCE: Medicare Plan Finder Tool
1

Quantity limits were the most common restriction observed and had the largest variation
across benchmark plans (Exhibit 3). This restriction is especially pertinent to LIS-receiving
beneficiaries who are able to purchase a three-month medication supply at the cost of a single
month’s co-pay. For those participants with one or more restricted medications, prior
authorizations were observed less frequently than step-therapy requirements under all
benchmark plans except Blue Cross (Exhibit 3). Both prior authorizations and step therapy
restrictions have the potential to decrease prescription drug plan costs, increase provider
involvement (and therefore provider costs) and potentially delay treatment of both acute and
chronic conditions (Raper et al., 2010).
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Discussion
The present study revealed large variation in costs and plan restrictions under each available
benchmark plan in California in 2010. Based on the participants in this study, only two of the six
plans were associated with the lowest OOP cost if all were randomly auto-enrolled in 2010. Also,
the presence of a single non-formulary medication resulted in substantial OOP cost increases.
Exhibit 3. Benchmark plan restrictions for study beneficiaries (n = 113)
Benchmark Plan Name1
AS
BC
BR
FH
Plan Restrictions
#
%
#
%
#
%
#
%
Frequency of Restriction
10
8.8
9
8.0
8
7.1
7
6.2
Prior Authorization
16 14.2 92
81.4 95 84.1 85 75.2
Quantity Limit
11
9.7
0
0.0 20 17.7 41 36.3
Step Therapy
% Medications Restricted
in Beneficiaries w/ >1
Restricted Medication
15.4
16.2
11.4
11.8
Prior Authorization
14.8
36.6
34.0
34.4
Quantity Limit
17.7
N/A
16.9
20.6
Step Therapy

#
9
34
25

FV

%

#

HN

%

8.0
6
30.1 106
22.1 22

5.3
93.8
19.5

10.7
15.9
15.7

13.3
47.6
14.3

1
AS, Advantage Star Plan by RxAmerica; BC, BlueCross; BR, Bravo Rx; FH, First Health Part D Premier; FV, Fox Value Plan; HN, Health Net
Orange Option 1
SOURCE: Medicare Plan Finder Tool

The primary study objective focused on the variability in benchmark plan EAC and drug
utilization restrictions at the individual beneficiary level. Exhibit 2 highlights potential financial
consequences of random assignment in study participants in 2010, as revealed through the
fourfold inter-plan variation in EAC and formulary coverage differences between benchmark
plans. It was also noted that on average only two of the six benchmark plans were the lowest
EAC benchmark plan for each participant; range 18.6% to 46.9% (Exhibit 2). If extrapolated to
all California beneficiaries, this finding indicates that, on average, 66% of auto-enrolled
California beneficiaries in 2010 could have been assigned to a benchmark plan that was not
associated with the lowest annual cost. It has been reported that 20% of LIS-recipients were
enrolled in benchmark plans in 2009 that did not qualify as benchmark plans in 2010. As such, it
is estimated that CMS randomly reassigned 1.2 million LIS enrollees to a new benchmark plan
in 2010 (Summer, Hoadley, & Hargrave, 2010).
Through its own analysis, CMS has found that nearly 32% of randomly-assigned
beneficiaries took at least one non-formulary prescription medication (Levinson, 2006). In the
present study, an average 38% of study participants had at least one non-formulary medication,
with a fourfold difference between benchmark plans (14.2% versus 57.5%, Exhibit 2).
Additionally, assignment to a plan with one or more non-formulary medications was shown to,
on average, increase EAC over 15-fold.
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Previous data from Maine indicated that approximately 46% of Medicare beneficiaries
would be auto-enrolled into a benchmark plan covering fewer than 80% of their current
medications (U.S. GAO, 2007). Participants in this study had, on average, a 17.8% chance (range
of 3.5% to 31% between all 6 benchmark plans) of being assigned to a benchmark plan with a
formulary matching rate less than 80%. The smaller proportion of participants with formulary
matching rates < 80%, as compared to previous studies, must be weighed against the observed
20-fold potential increase in OOP cost. Clearly, the benefit design requiring Medicare
beneficiaries, including those with LIS, to pay full price for non-formulary medications resulted
in a large increase in OOP costs for study participants and offset copayment and coinsurance
reductions afforded by their dual-eligible subsidy status.
In addition to supporting potential cost implications of random assignment seen in other
studies, the present study also found that 4% of participants would pay lower total OOP costs by
enrolling into an enhanced plan rather than an available benchmark plan. For these participants,
the increased expense of paying a monthly premium differential above the benchmark amount
was less costly than paying the full cost for non-formulary medications. Despite the small sample
size of this study, this finding lends weight to the potential implication of allowing beneficiary
assignment to enhanced plans (Hoadley et al., 2008).
Though the Medicare Part D benefit includes significant financial provisions for LISrecipients, the benefit can only be maximized if beneficiaries become fully aware of all available
afforded resources. The necessity of beneficiary-centered assignment has been downplayed by
CMS due to avenues available to LIS-receiving beneficiaries, including the prerogative to switch
PDPs at any time during the course of the year, or by taking a more proactive approach and
switching to medications that are on their existing plan formulary (U.S. GAO, 2007). Despite
these provisions, our data revealed that only 9% of the study sample switched plans outside of
the open enrollment period. Although there are potential channels available to LIS beneficiaries
whose medications are not on the plan formulary, including requesting an exception, obtaining
a new prescription, taking medication less frequently than prescribed, paying for the full cost of
the medication, or changing to a plan which covers their medication, all of the these avenues can
be complex, burdensome, and/or put the patient at undue risk (Hoadley et al., 2007; U.S. GAO
2007; Nemore & Gottlich, 2006).
Based on the congruency of our findings with larger studies, we too espouse the position
that CMS should move away from random assignment to one that considers the medication
regimen of each LIS-recipient when placing them in a benchmark plan (Hoadley et al.,
2007; U.S. GAO 2007; Hoadley et al., 2008). We argue that the primary objective of beneficiarycentered assignment should be to lower beneficiary, and not federal government, costs
associated with Medicare Part D. By preventing OOP cost increases, medication compliance is
more likely maintained, and unnecessary medical, hospital and emergency room costs might be
averted. To help curb the cost of implementing a program which unilaterally adopts beneficiarycentered assignment, we suggest that those beneficiaries who are at high risk of non-compliance
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related adverse events (e.g., based on prescription utilization or previous Medicare costs) should
be prioritized to receive such a service. In terms of the feasibility of implementing a system
based on beneficiary-centered assignment, a report conducted for the Medicare Payment
Advisory Commission concluded that such a system is possible for LIS-receiving beneficiaries,
with minimal disruptive effect or economic costs of providing such service (Hoadley et al.,
2007).
To date, the idea of beneficiary-centered assignment has been met with some resistance
from CMS. With regards to assigning beneficiaries to a benchmark plan based on their
prescription drug utilization pattern, CMS has previously taken the inflexible position that “we
do not accept the premise that exact matches are necessary or desirable” (U.S. GAO, 2007).
Additionally, CMS has retorted that it is statutorily mandated to randomly enroll LIS-receiving
beneficiaries to a benchmark plan (U.S. GAO, 2007). As such, CMS argues that it does not have
the discretion to enroll beneficiaries into a plan based on their specific prescription drug usage
patterns (U.S. GAO, 2007). An alternative approach that could be employed by CMS is to
require broader formulary coverage for benchmark plans. This would alleviate some of the
variation in plan formulary coverage and decrease the potential for suboptimal plan assignment.
In response to concerns raised by CMS, the U.S. Government Accountability Office
recommended that states be given the authority to use alternative enrollment methods, such as
beneficiary-centered assignment, when assigning LIS-recipients to benchmark plans (U.S. GAO,
2007). Furthermore, as of 2012, beneficiary-centered assignment is permissible instead of
random assignment by Section 1205 of the Health Care reform proposal (HR 3200; America’s
Affordable Health Choices Act, 2009). Though we recognize the potentially onerous
implications of designing a system for individual-level reexamination of benchmark plan
assignment, the potential economic savings to both the LIS-recipient and the government seem
to justify the implementation of such a system.
The congruency of our findings with other reports indicates that expansion into other
regions and larger sample sizes may be justified. An extension of this study that would likely be
of interest to policy-makers would examine the cost savings at a societal level, including both
beneficiary and governmental savings of a beneficiary-centered system of assignment.
Additionally, a prospective study which examines actual beneficiary behavior when faced with
potentially high OOP medication costs, or barriers to prescription drug access through the
implementation of restriction processes, is recommended for future consideration and may shed
light on the potential impact of drug costs on non-drug related Medicare costs.
A key limitation of this study was the small sample size (n = 113) of LIS-receiving
Medicare beneficiaries who self-selected to participate in this study. Participants may have been
more likely than the general LIS-eligible Medicare population to need assistance and we
recognize that this was not a randomized sample of Medicare beneficiaries residing in
California. However, the results from this study tend to coincide with previous research and
analyses; therefore, they lend weight to the validity of our findings. This is the first study to
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report individual-level cost and drug-restriction use for regional benchmark plans in any region.
As such, the novelty of these findings must be weighed against the potential for generalization.

Conclusion
The present study highlights the potential variability in OOP costs for LIS-recipients under each
of the available benchmark plans in California. Much of this variability was explained by the
number of beneficiary medications that were not on the benchmark plan formulary. The similar
results of this study, as compared to other larger reports, indicate that renewed attention should
be placed on the viability of beneficiary-centered assignment for all LIS-recipients. Additionally,
we found that targeted assistance to a vulnerable population of beneficiaries may help minimize
both their OOP costs and potential challenges they face with regard to their Medicare Part D
benefit.
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